Soleno Therapeutics announces publication of results from Phase 3 trial of DCCR

Soleno Therapeutics announced that results from the Company’s previously completed Phase 3 DESTINY PWS trial of DCCR Extended-Release tablets for the treatment of Prader-Willi Syndrome have been published in a peer-reviewed journal. The article, entitled, "Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial," was published in The Journal of Clinical Endocrinology and Metabolism. "We are pleased that the data from the C601 study of DCCR in PWS have been published in a prestigious peer-reviewed journal, JCEM," said Anish Bhatnagar, M.D., CEO of Soleno Therapeutics. "Based on the promising results from the trial, as well as discussions with the U.S. Food and Drug Administration, we initiated a randomized withdrawal period of the open-label Phase 3 extension study C602, which has the potential to support the submission of a New Drug Application. Trial subjects are currently being randomized at our clinical sites."